BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Clearside Biomedical, Inc. CLSDQ
11 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$1.7M
▼ 79.8% vs FY2023
EPS · FY24
$-0.47
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
-2064.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.7M
Revenue, FY2024 · full 11-year series below
Revenue
Net income
The company lost 2064 cents on every revenue dollar this year.
Per share
USD -0.47
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin-1735.7%
Net margin-2064.4%
Return on assets-116.2%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−5.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−61.7%
−5.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.08B
Shares outstanding, FY2024
Change, 5 years+72.4%
Change, 10 years—
The share count grew 72% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 25.1M
total assets, end of FY2024
Total assetsUSD 25.1M
EquityUSD -38.9M
CashUSD 20.0M
Current ratio4.44×
Equity funds -155% of total assets.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−0.47
−0.53
−0.55
0.01
−0.39
−0.81
−2.69
−2.33
−1.97
−7.54
−5.86
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
−135.6
1.6
−182.8
−177.0
−367.8
−126.7
−147.9
·
·
Shares out B
0.08
0.06
0.06
0.06
0.05
0.04
0.03
0.03
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 31
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed